Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) - Net Assets
Based on the latest financial reports, Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has net assets worth $495.96 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($514.10 Million) and total liabilities ($18.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Drugs Made In America Acquisition II Cor balance sheet independence to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $495.96 Million |
| % of Total Assets | 96.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Drugs Made In America Acquisition II Corp. Ordinary Shares - Net Assets Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition II Corp. Ordinary Shares's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Drugs Made In America Acquisition II Cor stock valuation.
Annual Net Assets for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
The table below shows the annual net assets of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2025. Also explore how fast is Drugs Made In America Acquisition II Cor growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $487.16 Million | +417477.61% |
| 2024-12-31 | $-116.72K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Drugs Made In America Acquisition II Corp. Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1762447700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $504.94 Million | 103.65% |
| Total Equity | $487.16 Million | 100.00% |
Drugs Made In America Acquisition II Corp. Ordinary Shares Competitors by Market Cap
The table below lists competitors of Drugs Made In America Acquisition II Corp. Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589
|
$647.35 Million |
|
First Watch Restaurant Group Inc
NASDAQ:FWRG
|
$647.36 Million |
|
Sobute New Materials Co Ltd
SHG:603916
|
$647.51 Million |
|
Catapult Group International Ltd
AU:CAT
|
$647.54 Million |
|
Algoma Central Corporation
TO:ALC
|
$647.08 Million |
|
Citycon Oyj
HE:CTY1S
|
$647.05 Million |
|
PNE AG
XETRA:PNE3
|
$646.60 Million |
|
Sincere Navigation Corp
TW:2605
|
$646.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Drugs Made In America Acquisition II Corp. Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -116,719 to 487,158,973, a change of 487,275,692.
- Net income of 4,187,050 contributed positively to equity growth.
- New share issuances of 502,000,000 increased equity.
- Other factors decreased equity by 18,911,358.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.19 Million | +0.86% |
| Share Issuances | $502.00 Million | +103.05% |
| Other Changes | $-18.91 Million | -3.88% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Drugs Made In America Acquisition II Corp. Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.28x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $0.00 | $10.17 | x |
| 2025-12-31 | $36.66 | $10.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Drugs Made In America Acquisition II Corp. Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (0.86%) is above the historical average (0.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-140.05K |
| 2025 | 0.86% | 0.00% | 0.00x | 1.04x | $-44.53 Million |
Industry Comparison
This section compares Drugs Made In America Acquisition II Corp. Ordinary Shares's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $203,465,471
- Average return on equity (ROE) among peers: -9.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) | $495.96 Million | 0.00% | 0.04x | $647.19 Million |
| Artius II Acquisition Inc. (AACB) | $214.29 Million | 0.06% | 0.07x | $234.83 Million |
| Artius II Acquisition Inc. Units (AACBU) | $214.29 Million | 0.06% | 0.07x | $269.37 Million |
| Armada Acquisition Corp. II Class A Ordinary Shares (AACI) | $147.40 Million | -2.46% | 0.02x | $256.50 Million |
| Abony Acquisition Corp. I Class A Ordinary Share (AACO) | $-74.71 | 0.00% | 0.00x | $236.71 Million |
| Apogee Acquisition Corp Class A Ordinary Shares (AACP) | $-13.88 | 0.00% | 0.00x | $178.44 Million |
| Ares Acquisition Corporation II (AACT) | $528.66 Million | 4.92% | 0.04x | $587.05 Million |
| AA Mission Acquisition Corp. (AAM) | $373.20 Million | -150.35% | 14.85x | $388.34K |
| Altenergy Acquisition Corp (AEAE) | $4.84 Million | 51.14% | 2.71x | $72.22 Million |
| Activate Energy Acquisition Corp. Class A Ordinary Share (AEAQ) | $223.53 Million | 0.00% | 0.04x | $238.34 Million |
| American Exceptionalism Acquisition Corp. A (AEXA) | $328.45 Million | 0.00% | 0.06x | $387.32 Million |
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp… Read more